ArticleBioinformation2024
Seroprevalence of HCV infection among Indian patients with hemodialysis.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) exists as the most common hepatotropic disease with a severe complication in significant patients. Maximum incidence of HCV infection occurred specifically in hemodialysis patients and they were related with increased illness and fatality rate. Therefore, it is of interest to know the seroprevalence of HCV infections in hemodialysis patients using anti-HCV and PCR diagnosis. Hence, this study was carried out at a tertiary care hospital for a period of 12 months. 92 blood samples were collected and subjected for the detection of HCV antibodies using ELISA followed by RT-PCR. Out of 92 HD patient samples, 7 were positive for Anti-HCV and 9 samples showed positive for HCV RNA. Thus, ELISA has less sensitivity with false negative rate for identification of HCV infection. Thus, hemodialysis patients should be routinely screened for HCV using RT-PCR for adequate management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.